NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 5.2018

• DOI: 10.6004/jnccn.2018.0062
• Publication Date: 2018-07-13T09:15:24Z
• Authors: David S. Ettinger; Dara L. Aisner; Douglas E. Wood; Wallace Akerley; Jessica Bauman; Joe Y. Chang; Lucian R. Chirieac; Thomas A. D'Amico; Thomas J. Dilling; Michael Dobelbower; Ramaswamy Govindan; Matthew A. Gubens; Mark Hennon; Leora Horn; Rudy P. Lackner; Michael Lanuti; Ticiana A. Leal; Rogerio Lilenbaum; Jules Lin; Billy W. Loo; Renato Martins; Gregory A. Otterson; Sandip P. Patel; Karen Reckamp; Gregory J. Riely; Steven E. Schild; Theresa A. Shapiro; James Stevenson; Scott J. Swanson; Kurt Tauer; Stephen C. Yang; Kristina Gregory; Miranda Hughes
• Keywords: Lung Neoplasms; Medical Oncology; Progression-Free Survival; United States; 3. Good health; 03 medical and health sciences; Antineoplastic Agents, Immunological; 0302 clinical medicine; Drug Resistance, Neoplasm; Carcinoma, Non-Small-Cell Lung; Antineoplastic Combined Chemotherapy Protocols; Mutation; Biomarkers, Tumor; Disease Progression; Humans; Molecular Targeted Therapy; Societies, Medical; Randomized Controlled Trials as Topic

The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the targeted therapy and immunotherapy sections in the NCCN Guidelines. For the 2018 update, a new section on biomarkers was added.